Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBenigno, Arcangelo
dc.contributor.authorEsposito, Ennio
dc.contributor.authorCrescimanno, Giuseppe
dc.contributor.authorMatteo, Vincenzo di
dc.contributor.authorDi Giovanni, Giuseppe
dc.identifier.citationBenigno, A., Esposito, E., Crescimanno, G., Di Matteo, V., & Di Giovanni, G. (2007). Inflammation in Parkinson’s disease : therapeutic implications. In G. Di Giovanni & E. Esposito (Eds.), The basal ganglia pathophysiology : recent advances 2007. (pp. 159-189). Kerala: Transworld Research Network.en_GB
dc.description.abstractParkinson’s disease (PD) is known to be a chronic and progressive neurodegenerative disease caused by a selective degeneration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNc). A large body of experimental evidence indicates that the factors involved in the pathogenesis of this disease are several, occurring inside and outside the DAergic neuron. Recently, the role of the neuron-glia interaction and the inflammatory process, in particular, has been the object of intense study by the research community. It seems to represent a new therapeutic approach opportunity for this neurological disorder. Indeed, it has been demonstrated that the cyclooxygenase type 2 (COX-2) is up-regulated in SNc DAergic neurons in both PD patients and animal models of PD and, furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) pre-treatment protects against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6 hydroxydopamine (6-OHDA)-induced nigro-striatal dopamine degeneration. Moreover, recent epidemiological studies have revealed that the risk of developing PD is reduced in humans who make therapeutical use of NSAIDs. Consequently, it is hypothesized that they might delay or prevent the onset of PD. However, whether or not these common drugs may also be of benefit to those individuals who already have Parkinson’s disease has not as yet been shown. In this paper, evidence relating to the protective effects of aspirin or other NSAIDs on DAergic neurons in animal models of Parkinson’s disease will be discussed. In addition, the pharmacological mechanisms by which these molecules can exert their neuroprotective effects will be reviewed. Finally, epidemiological data exploring the effectiveness of NSAIDs in the prevention of PD and their possible use as adjuvants in the therapy of this neurodegenerative disease will also be examined.en_GB
dc.publisherTransworld Research Networken_GB
dc.subjectParkinson's diseaseen_GB
dc.titleInflammation in Parkinson’s disease : therapeutic implicationsen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
Appears in Collections:The basal ganglia pathophysiology : recent advances

Files in This Item:
File Description SizeFormat 
8.pdf357.36 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.